6 months ago
BIIB
AnalystsAndrew TsaiAndrew Tsai's Stock Forecasts
AnalystsAndrew Tsai
Analyst Ranking
Top 30%
#1553 out of 5223 analysts
Average Return
+2.89%
Win Rate
52%15 out of 29
Risk vs Reward
Poor
Good
Andrew Tsai's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Stoke Therapeutics IncSTOK | +153.48% | $13.22 | $33.51 | 2025-07-18 - 2026-03-20 | Strong Buy |
Cerevel Therapeutics Holdings IncCERE | +139.30% | $14.20 | $33.98 | 2020-11-23 - 2021-11-22 | Strong Buy |
Praxis Precision Medicines IncPRAX | +83.34% | $162.71 | $298.31 | 2025-10-16 - 2026-03-20 | Strong Buy |
Axsome Therapeutics IncAXSM | +59.31% | $98.50 | $156.92 | 2025-04-07 - 2026-03-20 | Strong Buy |
Alto Neuroscience IncANRO | +51.20% | $14.20 | $21.47 | 2025-11-12 - 2026-03-20 | Strong Buy |
Andrew Tsai Analyst Color
Get additional color on Andrew Tsai's coverage of popular stocks
a year ago
SRPT
Andrew Tsai's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Axsome Therapeutics IncAXSM | 2 | Strong Buy | $245.00 | +56.13% | Maintains | 2 months ago |
Definium Therapeutics IncDFTX | 1 | Strong Buy | $30.00 | +63.04% | Initiates Coverage On | 2 months ago |
Vistagen Therapeutics IncVTGN | 3 | Hold | $0.90 | +47.78% | Downgrades | 3 months ago |
Moderna IncMRNA | 1 | Hold | $30.00 | -41.61% | Initiates Coverage On | 3 months ago |
Praxis Precision Medicines IncPRAX | 2 | Strong Buy | $450.00 | +50.85% | Maintains | 3 months ago |
Maplight Therapeutics IncMPLT | 1 | Strong Buy | $32.00 | +82.23% | Initiates Coverage On | 4 months ago |
Alto Neuroscience IncANRO | 2 | Strong Buy | $25.00 | +16.44% | Maintains | 4 months ago |
Avadel Pharmaceuticals PLCAVDL | 1 | Hold | $20.00 | -7.58% | Downgrades | 5 months ago |
Akero Therapeutics IncAKRO | 1 | Hold | $56.00 | +2.47% | Downgrades | 5 months ago |
Biogen IncBIIB | 1 | Strong Buy | $190.00 | +4.71% | Initiates Coverage On | 6 months ago |
Sarepta Therapeutics IncSRPT | 3 | Strong Buy | $35.00 | +109.71% | Maintains | 8 months ago |
Stoke Therapeutics IncSTOK | 1 | Strong Buy | $30.00 | -10.47% | Initiates Coverage On | 8 months ago |
Bridgebio Pharma IncBBIO | 1 | Strong Buy | $70.00 | +2.13% | Initiates Coverage On | 8 months ago |
Verona Pharma PLCVRNA | 1 | Strong Buy | $110.00 | +2.89% | Maintains | 9 months ago |
Rocket Pharmaceuticals IncRCKT | 2 | Hold | $2.50 | -39.61% | Downgrades | 10 months ago |
Ke Holdings IncBEKE | 2 | Strong Buy | $27.00 | N/A | Maintains | a year ago |
Marinus Pharmaceuticals IncMRNS | 1 | Hold | $0.50 | N/A | Downgrades | a year ago |
Relmada Therapeutics IncRLMD | 2 | Strong Buy | $13.00 | N/A | Upgrades | 2 years ago |
Rapport Therapeutics IncRAPP | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 2 years ago |
Fusion Pharmaceuticals IncFUSN | 1 | Hold | $21.00 | N/A | Downgrades | 2 years ago |
Lexicon Pharmaceuticals IncLXRX | 1 | Hold | $3.00 | N/A | Initiates Coverage On | 3 years ago |
Leonabio IncLONA | 2 | Hold | $30.00 | N/A | Downgrades | 4 years ago |
Vigil Neuroscience IncVIGL | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 4 years ago |
Intra Cellular Therapies IncITCI | 1 | Strong Buy | $70.00 | N/A | Maintains | 5 years ago |
Ataibeckley IncATAI | 1 | Strong Buy | $27.00 | N/A | Initiates Coverage On | 5 years ago |
Cerevel Therapeutics Holdings IncCERE | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 5 years ago |
Xenon Pharmaceuticals IncXENE | 1 | Strong Buy | $23.00 | N/A | Assumes | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.